Delivery Order SPE2DB24D2215-SPE2DB25FGSVE

Award Date 5/2/25
Potential Completion Date 5/5/25
Potential Value $7.3K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price delivery order issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of 4,567,927,167 units of the GARDASIL 9 vaccine syringe (0.5 mL), with a ceiling value of $17,718.03 and a period of performance through April 16, 2025. The contract is not set aside and was awarded on April 15, 2025. AmerisourceBergen Drug Corp holds a significant...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of GARDASIL 9 syringes. The contract has a ceiling value of $5,571.64 and an ultimate completion date of April 17, 2025. The contract is not designated as a set-aside. AmerisourceBergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which provides a...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $5,242.38, is for the delivery of 4,568,116,064 units of the GARDASIL 9 vaccine syringe (0.5 mL). The contract has an ultimate completion date of May 5, 2025 and was awarded on May 2, 2025. AmerisourceBergen Drug Corp holds a larger $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of GARDASIL 9 SYRINGE 0.5ML, a vaccine product, with a ceiling value of $1,747.46 and a period of performance through April 18, 2025. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999.00 that AmerisourceBergen holds with the DLA...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of GARDASIL 9 syringes, a vaccine product, with a ceiling value of $21,869.00. The contract type is Firm Fixed Price, and it has an ultimate completion date of April 23, 2025. The contract is not set aside and was competitively awarded. AmerisourceBergen Drug Corp holds a significant...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $3,390.54, is for the delivery of GARDASIL 9 SYRINGE 0.5ML, a vaccine product. The contract is a firm fixed-price delivery order, with an ultimate completion date of April 28, 2025. The contract is not set-aside and was awarded on April 25, 2025. AmerisourceBergen Drug Corp holds a significant...
This is a firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a pharmaceutical distribution company, to provide GARDASIL 9 vaccine syringes. The contract has a ceiling value of $12,421.96 and a performance period through March 13, 2024. AmerisourceBergen Drug Corp is the prime contractor on this order, which is a part of a larger indefinite delivery contract (IDC) with DLA valued up to $999,999,999.00 through December 31, 2025. This IDC...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Gardasil 9 syringes, a vaccine product, and has a ceiling value of $8,352.27. The contract is a firm-fixed-price, non-set-aside contract with an ultimate completion date of April 10, 2025. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the...
This is a Delivery Order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the procurement of GARDASIL 9 SYRINGE 0.5ML, a vaccine product, and has a ceiling value of $26,152.42. The contract is a Firm Fixed Price type and runs through March 31, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of GARDASIL 9 syringes, a vaccine product, with a ceiling value of $15,173.02 and a period of performance through April 11, 2025. The contract is a firm fixed-price delivery order, without any set-aside designation, indicating open competition. AmerisourceBergen Drug Corp holds a...
  • SPE2DB24D2215
    Indefinite Delivery Contract
  • SPE2DB24D2215-SPE2DB25FGSVE
    Delivery Order

This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of GARDASIL 9 vaccine syringes. The contract has a ceiling value of $7,295.92 and an ultimate completion date of May 5, 2025. The contract is not set-aside and was awarded on May 2, 2025. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999.00, which provides a comprehensive global pharmaceutical support vehicle with a performance period extending through December 2026. This delivery order is part of the company's broader role as a critical vendor supporting federal medical procurement needs, particularly for military and veteran healthcare systems.

Generated 8/3/25, 1:25 AM